Table 1.
Comparison of clinical traits of α-fetoprotein-producing gastric cancer and non-α-fetoprotein-producing gastric cancer patientsa
| Characteristics | AFPGCs, n (%) | Non-AFPGCs, n (%) | Studies, n (study number) |
|---|---|---|---|
| Gender, N |
74 |
808 |
3 (1, 2, 6) |
| Male |
54 (73.0) |
579 (71.7) |
|
| Female |
20 (27.0) |
229 (28.3) |
|
| Tumor site |
54 |
483 |
3 (2, 5, 6) |
| Antrum |
23 (42.5) |
144 (29.8) |
|
| Body of stomach |
15 (27.8) |
156 (32.3) |
|
| Cardia or bottom of stomach |
15 (27.8) |
177 (36.7) |
|
| Whole stomach |
1 (1.9) |
6 (1.2) |
|
| Diameter of tumor,bN |
83 |
989 |
5 (1 to 3, 5, 6) |
| <3 cm |
19 (22.9) |
373 (37.7) |
|
| >3 cm |
64 (77.1) |
616 (62.3) |
|
| Diameter of tumor,bN |
53 |
567 |
2 (1, 6) |
| <5 cm |
34 (64.2) |
487 (85.9) |
|
| >5 cm |
19 (35.8) |
80 (14.1) |
|
| Borrmann type, N |
39 |
442 |
2 (2, 3) |
| I or II |
16 (41.0) |
197 (44.6) |
|
| III or IV |
23 (59.0) |
245 (55.4) |
|
| Histopathological type, N |
32 |
436 |
1 (1) |
| Papillary cystadenocarcinoma |
3 (9.4) |
212 (48.6) |
|
| Tubular adenocarcinoma |
11 (34.3) |
45 (10.3) |
|
| Mucinous adenocarcinoma |
3 (9.4) |
94 (21.6) |
|
| Signet ring cell carcinoma |
6 (18.8) |
57 (13.1) |
|
| Undifferentiated |
9 (28.1) |
28 (6.4) |
|
| Differentiation degree, N |
86 |
919 |
4 (1, 2, 5, 6) |
| Well or moderate |
12 (14.0) |
290 (31.6) |
|
| Poor or none |
74 (86.0) |
629 (68.4) |
|
| Serosal infiltration N |
67 |
614 |
4 (3 to 6) |
| T1 or T2 |
26 (38.8) |
285 (46.4) |
|
| T3 or T4 |
41 (61.2) |
329 (53.6) |
|
| Lymph node metastasis,cN |
120 |
1291 |
6 (1 to 6) |
| No |
18 (15.0) |
492 (38.1) |
|
| Yes |
102 (85.0) |
799 (61.9) |
|
| Lymph node metastasis,cN |
55 |
613 |
3 (2 to 4) |
| 0 |
6 (10.9) |
235 (38.3) |
|
| 1 - 4 |
7 (12.7) |
212 (34.6) |
|
| > 4 |
42 (76.4) |
166 (27.1) |
|
| Liver metastasis, N |
120 |
1291 |
6 (1 to 6) |
| Yes |
68 (56.7) |
255 (19.8) |
|
| No |
52 (43.3) |
1,036 (80.2) |
|
| Stage, N |
87 |
1049 |
4 (1 to 4) |
| I |
4 (4.6) |
198 (18.9) |
|
| II |
14 (16.2) |
366 (34.9) |
|
| III |
23 (26.4) |
325 (31.0) |
|
| IV |
46 (52.8) |
160 (15.2) |
|
| VEGF expression, N |
21 |
241 |
1 (2) |
| Positive | 19 (90.5) | 162 (67.2) |
aAFPGC, α-fetoprotein-producing gastric cancer; VEGF, vascular endothelial growth factor. bBecause of the different ways of reporting these data, the studies were evaluated twice. In studies 1 through 3 and study 5, the cut-off diameter is 3 cm. In studies 1 and 6, the cut-off diameter is 5 cm. cIn studies 2 through 4, the number of metastatic lymph nodes is available. In other studies, the number is not available.